STAAR Surgical Stock Slides as In-Line Revenue Disappoints Investors

STAAR Surgical (NASDAQ: STAA) shares declined in pre-market trading after its preliminary second-quarter sales results failed to meaningfully exceed analyst expectations. The company announced late Tuesday that it anticipates Q2 net sales to surpass $90 million, a figure that more than doubles the $44.3 million reported in the same quarter last year but lands just shy of the Wall Street consensus of approximately $90.2 million.

A 'Sell the News' Reaction

The in-line revenue figure, rather than a significant beat, prompted a classic "sell the news" dynamic among investors. The stock initially fell roughly 8.4% in after-hours trading before paring some losses to a 5.6% decline in the pre-market session.

This market reaction highlights investor sensitivity to execution, particularly as the company has not reinstated formal financial guidance. Even with substantial year-over-year growth, the result was not enough to satisfy expectations that had been built on prior momentum.

Analyst Cautious on Leadership, Guidance

Following the announcement, analysts at Canaccord Genuity reiterated a Buy rating and a $32 price target on the stock. However, the firm noted it would wait for the full second-quarter results, scheduled for August 12, 2026, before revising its estimates.

Ad

The firm flagged two key issues creating uncertainty:

• Management: The company is currently operating under interim co-CEOs, and analysts are looking for more stability with permanent leadership.
• Guidance: The absence of formal financial guidance from the company makes it more difficult for investors to gauge future performance with conviction.

Regional Performance and Market Headwinds

While STAAR reported strong performance in key markets, with double-digit percentage gains in the Americas and sequential growth in China, it faced a regional headwind. Net sales in the Europe, Middle East, and Africa (EMEA) region saw a low single-digit percentage decline, which the company attributed to ongoing turmoil in the Middle East.

The stock's decline was compounded by a broader risk-off sentiment in the markets. Negative pre-market performance for major indices, including the NASDAQ and S&P 500, created additional selling pressure on growth-oriented healthcare stocks like STAAR.